Atorvastatin hemicalcium salt

Pricing Availability   Qty
Cat.No. 3776 - Atorvastatin hemicalcium salt | C33H34FN2O5.½Ca | CAS No. 134523-03-8
Description: Potent HMG-CoA reductase inhibitor
Alternative Names: Lipitor
Chemical Name: (R,R)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt
Purity: ≥99% (HPLC)
Datasheet
Citations (1)
Reviews (1)
Literature

Biological Activity

Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Compound Libraries

Atorvastatin hemicalcium salt is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 577.67
Formula C33H34FN2O5.½Ca
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 134523-03-8
PubChem ID 60822
InChI Key FQCKMBLVYCEXJB-MNSAWQCASA-L
Smiles [Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1)C1=CC=CC=C1.CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1)C1=CC=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 57.77 100

Preparing Stock Solutions

The following data is based on the product molecular weight 577.67. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.73 mL 8.66 mL 17.31 mL
5 mM 0.35 mL 1.73 mL 3.46 mL
10 mM 0.17 mL 0.87 mL 1.73 mL
50 mM 0.03 mL 0.17 mL 0.35 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Istvan et al (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 1160 PMID: 11349148

Vaughan et al (2004) Update on STAT: 2003. Circulation 110 886 PMID: 15313959

Santodomingo-Garzon et al (2006) AtoVas inhibits inflammatory hypernociception. Br.J.Pharmacol. 149 14 PMID: 16865092

Turner et al (2007) Comparison of the efficacies of five different STAT on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J.Cardiovasc.Pharmacol. 50 458 PMID: 18049315


If you know of a relevant reference for Atorvastatin hemicalcium salt, please let us know.

View Related Products by Target

View Related Products by Product Action

View all HMG-CoA Reductase Inhibitors

Keywords: Atorvastatin hemicalcium salt, Atorvastatin hemicalcium salt supplier, HMG-CoA, reductases, inhibitors, inhibits, cholesterol, biosynthesis, LDL, Pfizer, statins, Lipitor, Reductase, 3776, Tocris Bioscience

1 Citation for Atorvastatin hemicalcium salt

Citations are publications that use Tocris products. Selected citations for Atorvastatin hemicalcium salt include:

Rojo-Arreola et al (2014) Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One 9 e87594 PMID: 24489942


Do you know of a great paper that uses Atorvastatin hemicalcium salt from Tocris? Please let us know.

Reviews for Atorvastatin hemicalcium salt

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Atorvastatin hemicalcium salt?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Atorvastatin effect as Rho inhibitor.
By Anonymous on 03/26/2018
Assay Type: In Vitro
Species: Other
Cell Line/Tissue: chondrocyte

used as alternative to simvastatin

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.